Search Share Prices
Syncona investment Autolus confirms Nasdaq float plans
Cancer-focused biopharmaceutical company Autolus, in which FTSE 250 healthcare investment firm Syncona has a 38% stake, has filed for an initial public offering on the New York stock exchange.
While the number of shares to be sold and the pricing terms for the proposed Nasdaq IPO were yet to be determined, Syncona confirmed that Autolus had filed a registration statement with the US Securities and Exchange Commission and intends to apply to list itself on the Nasdaq Global Market under the ticker symbol "AUTL".
Syncona highlighted that while Autolus' registration statement relating to its American depository shares had been filed with the SEC but had not yet become effective.
Back in September, Syncona's investment in Autolus, which is developing and commercialising next-generation engineered T-cell therapies to combat cancer, was written up by £19.2m to £88.6m, while its ownership stake in the business increased to a total 38.4% shareholding.
As of 1030 BST, Syncona shares had ticked ahead 0.13% to 207.78p.